Evidence map›Paper›PMID 38974608›Full record

ArticleJIMD reports2024

Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type Ia.

A B Schreuder, R J Overduin, N C Peltenburg, L de Boer, F A J A Bodewes, T G J Derks

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JIMD reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

A B SchreuderDepartment of Metabolic Diseases, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands.ORCID https://orcid.org/0000-0002-9050-5808
R J OverduinDepartment of Metabolic Diseases, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands.
N C PeltenburgDepartment of Metabolic Diseases and internal medicine Erasmus Medical Center Rotterdam The Netherlands.
L de BoerDepartment of Metabolic Diseases, Amalia Children's Hospital Radboud University Medical Center Nijmegen The Netherlands.
F A J A BodewesDepartment of Pediatric Hepatology and Gastroenterology, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands.
T G J DerksDepartment of Metabolic Diseases, Beatrix Children's Hospital University Medical Center Groningen, University of Groningen Groningen The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No sensitive tumor marker for hepatocellular carcinoma (HCC) is available for patients with glycogen storage disease type Ia (GSDIa), in whom alpha-fetoprotein and carcino-embryonic antigen levels often remain normal. We describe increased levels of the HCC tumor marker des-gamma-carboxy prothrombin (DCP) in GSDIa patients with HCC. In one case DCP levels normalized after liver transplantation. We recommend including DCP as a screening HCC tumor marker in the surveillance of patients with GSDIa.

Indexed as

des‐gamma‐carboxy prothrombinglycogen storage disease type Ihepatocellular adenomahepatocellular carcinomatumor markers

Identifiers

PMID38974608
PMCPMC11224497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.